10-Q · August 11, 2026
LENZ delivered strong commercial momentum in Q2 2026, with revenue of $5.486 million, approximately 27,000 VIZZ packs sold and delivered, and EPS of $(1.02) ahead of consensus. However, the quarter remained deeply…
Earnings analysis · 10-Q
LENZ earnings analysis
Filed November 3, 2026 · Our reading of the company's report
The latest report
LENZ established continued VIZZ product revenue of $2.599 million, but total Q3 revenue of $3.384 million declined approximately 73% year over year because license revenue fell to $0.785 million from $12.500 million.…
Read full summary
LENZ established continued VIZZ product revenue of $2.599 million, but total Q3 revenue of $3.384 million declined approximately 73% year over year because license revenue fell to $0.785 million from $12.500 million. Gross margin compressed to 63.5%, operating margin was approximately negative 972.2%, and net loss widened to $31.0 million as commercial spending increased. The $197.3 million liquidity balance supports management’s stated expectation of at least 12 months of operations, but $94.606 million of operating cash burn through nine months, a 75% workforce reduction, a planned $5 million restructuring charge and the December 1 CEO transition create significant execution and financing risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.99
What stood out
-
VIZZ sales offset sharply lower license revenue
Revenue was $3.384 million, down approximately 32% from $5.0 million in Q2 2026 and approximately 73% from $12.500 million in Q3 2025. Product sales contributed $2.599 million, while license revenue was $0.785 million.
-
Commercial product sales established
VIZZ product sales were $2.599 million, driven by approximately 38,000 packs sold and delivered. Management also reported that telehealth availability began in July 2026, expanding the prescribing and fulfillment channel.
-
Gross margin compressed with commercialization
Gross margin declined to approximately 63.5% from 94.9% in Q2 2026 and 100.0% in Q3 2025, reflecting $454,000 of cost of sales on $2.599 million of product sales.
-
Commercial investment drove higher expenses
Selling, general and administrative expense increased 30% year over year to $35.848 million from $27.596 million, primarily due to a $7.3 million increase in commercial marketing, advertising and sales infrastructure expense.
-
Liquidity supports near-term operations
Cash, cash equivalents and marketable securities totaled $197.3 million at September 30, 2026. Management stated that existing liquidity is expected to support operations for at least the next 12 months.
-
First ex-U.S. approval expands opportunity
VIZZ received its first ex-U.S. regulatory approval in October 2026 when the UAE granted Product Marketing Authorization Approval, representing the first approval under the Lunatus License.
What to watch
-
Rapid cash burn may require financing
Net loss increased to $31.0 million from $16.7 million in Q3 2025, while operating cash used increased to $94.606 million for the nine months ended September 30, 2026 from $36.145 million in the prior-year period. Management warned that additional financing may be required if revenue and operating cash flow are insufficient.
-
Large restructuring creates execution risk
The October 28, 2026 strategic reorganization reduced headcount by approximately 75% to approximately 40 full-time employees and is expected to generate approximately $5 million of net restructuring charges, creating execution and continuity risk during commercialization.
-
CEO transition adds management risk
Effective December 1, 2026, the CEO will transition to a strategic advisor and the CFO will become interim CEO while continuing as CFO. The filing states that the leadership transition could disrupt operations and harm the business.
-
Presbyopia competition is intensifying
Competition increased with Ryzumvi approved in October 2026, alongside Qlosi, Yuvezzi and generic Vuity. The filing states that competing products could be safer, more effective, more convenient or less expensive than VIZZ.
-
Single-product concentration remains high
The company depends entirely on VIZZ and has no additional product candidates in its current development pipeline. Product revenue was only $2.599 million in Q3 2026, increasing dependence on successful adoption of a single commercial product.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management expects 2027 operating expenses of approximately $70 million to $75 million, excluding stock-based compensation, following the October 2026 strategic reorganization. Management also expects approximately $5 million of net restructuring charges in Q4 2026.
Earlier filings 4
10-Q · May 11, 2026
LENZ reported Q4 2026 results with revenue of $1.588 million, a decrease from $2 million in Q4 2025, translating to a year-over-year decline of 20.6%. EPS from continuing operations was -$1.16, more than the prior…
10-K · March 24, 2026
LENZ launched VIZZ (aceclidine ophthalmic solution) in the U.S. after FDA approval on July 31, 2025 and began retail distribution in November 2025; the company positions VIZZ as a differentiated, pupil‑selective miotic…
10-Q · November 5, 2025
LENZ Therapeutics reported a significantly increased revenue of $12.5 million in Q3 2025 from no revenue in the prior year's quarter, indicating strong progress following the FDA approval of its product VIZZ. Despite a…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.